Recent trends on the development of systems for cancer diagnosis and treatment by microfluidic technology
Source abstract
Abstract
Abstract Cancer is the second leading cause of non-accidental death in the world, accounting for roughly 9.6 million deaths in 2018. In the latter years, research in this domain has grown exponentially, as a way to provide deep insights into this malignancy, but also new tools for early diagnosis and efficient personalized treatment options. Microfluidic lab-on-a-chip technology has demonstrated a high potential on the design of new methodologies for cancer diagnosis, treatment and disease follow-up. Here, we present a detailed review on the application of the microfluidic platforms for the detection and separation of tumour cells from blood (liquid biopsy) and the development of new drug delivery systems for cancer conquering.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Microfluidic and Bio-sensing Technologies · 3D Printing in Biomedical Research · Microfluidic and Capillary Electrophoresis Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. WHO · 2018
2. International Agency for Research on Cancer · 2018
3. International Agency for Research on Cancer · 2018
4. WHO · 2017
5. Tumor markers — a bird’s eye view10.1016/j.ajoms.2016.07.006 ↗
6. c-Myc and cancer metabolism10.1158/1078-0432.CCR-12-0977 ↗
7. A review on the clinical utility of PSA in cancer prostate10.1007/s13193-012-0142-6 ↗
8. New technologies for human cancer imaging10.1200/JCO.2007.14.3065 ↗
9. Basic principles of radiation therapy of cancers
10. National Cancer Institute · 2015
11. Controlled drug delivery vehicles for cancer treatment and their performance, Signal Transduct
12. Cardiac side-effects of cancer chemotherapy10.1016/j.ijcard.2010.03.003 ↗
13. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients10.1097/01.gco.0000192996.20040.24 ↗
14. Inequality in the incidence and mortality of all cancers in the world
15. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
16. Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker10.1038/s41467-018-07214-w ↗
17. In vitro cytotoxicity and anticancer effects of citral nanostructured lipid carrier on MDA MBA-231 human breast cancer cells10.1038/s41598-018-38214-x ↗
18. Hyperthermia enhances photodynamic therapy by regulation of HCP1 and ABCG2 expressions via high level ROS generation10.1038/s41598-018-38460-z ↗
19. Introduction to microfluidics
20. The origins and the future of microfluidics10.1038/nature05058 ↗
21. Small but perfectly formed? Successes, challenges, and opportunities for microfluidics in the chemical and biological sciences10.1016/j.chempr.2017.01.009 ↗
22. Design, fabrication and characterization of drug delivery systems based on lab-on-a-chip technology10.1016/j.addr.2013.05.008 ↗
23. Microfluidics for combating antimicrobial resistance10.1016/j.tibtech.2017.07.008 ↗
24. Revisiting lab-on-a-chip technology for drug discovery10.1038/nrd3799 ↗
25. Point-of-care testing (POCT) diagnostic systems using microfluidic lab-on-a-chip technologies10.1016/j.mee.2014.09.024 ↗
26. Automatic smartphone-based microfluidic biosensor system at the point of care10.1016/j.bios.2018.03.018 ↗
27. Recent advances of controlled drug delivery using microfluidic platforms10.1016/j.addr.2017.09.013 ↗
28. Using microfluidic platforms to develop CNS-targeted polymeric nanoparticles for HIV therapy10.1016/j.ejpb.2018.01.014 ↗
29. Microfluidic assembly of a nano-in-micro dual drug delivery platform composed of halloysite nanotubes and a pH-responsive polymer for colon cancer therapy10.1016/j.actbio.2016.10.042 ↗
30. Microfluidic nanoassembly of bioengineered chitosan-modified FcRn-targeted porous silicon nanoparticles @ hypromellose acetate succinate for oral delivery of antidiabetic peptides10.1021/acsami.8b20821 ↗
31. Nuts and bolts: microfluidics for the production of biomaterials
32. pH and reactive oxygen species-sequential responsive nano-in-Micro composite for targeted therapy of inflammatory bowel disease
33. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy10.1021/nn403370e ↗
34. Cell-based high content screening using an integrated microfluidic device10.1039/b711513j ↗
35. Cell culture monitoring for drug screening and cancer research: a transparent, microfluidic, multi-sensor microsystem10.1039/C3LC50759A ↗
36. Aptamer-based microfluidic device for enrichment, sorting, and detection of multiple cancer cells10.1021/ac9012072 ↗
37. A microfluidic-based platform for tumour spheroid culture, monitoring and drug screening10.1039/C4LC00291A ↗
38. A review of microfluidic approaches for investigating cancer extravasation during metastasis10.1038/micronano.2017.104 ↗
39. Photothermal-responsive nanosized hybrid polymersome as versatile therapeutics codelivery nanovehicle for effective tumor suppression10.1073/pnas.1817251116 ↗
40. Microfluidic assisted one-step fabrication of porous silicon@acetalated dextran nanocomposites for precisely controlled combination chemotherapy10.1016/j.biomaterials.2014.10.079 ↗
41. Gold nanorods conjugated porous silicon nanoparticles encapsulated in calcium alginate nano hydrogels using microemulsion templates10.1021/acs.nanolett.7b05210 ↗
42. Microfluidic approaches for the design of functional materials10.1016/j.mee.2018.07.007 ↗
43. Microfluidic platforms for cell cultures and investigations10.1016/j.mee.2019.01.004 ↗
44. Microfluidic technologies for anticancer drug studies10.1016/j.drudis.2017.06.010 ↗
45. Applications of microfluidic chip technology in pharmaceutical analysis: a review10.1016/j.jpha.2018.12.001 ↗
46. Emerging techniques: whole-body screening and staging with MRI10.1002/jmri.20666 ↗
47. Fine-needle aspiration (FNA) biopsy: historical aspects10.2478/v10042-009-0027-x ↗
48. Tumour seeding following percutaneous needle biopsy: The real story!10.1016/j.crad.2011.05.012 ↗
49. Risk of tumor cell seeding through biopsy and aspiration cytology10.4103/2231-0762.129446 ↗
50. Pros: can tissue biopsy be replaced by liquid biopsy?10.21037/tlcr.2016.08.06 ↗
51. A fluid future for liquid biopsies10.1002/cncy.22087 ↗
52. The potential of liquid biopsies for the early detection of cancer10.1038/s41698-017-0039-5 ↗
53. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy10.1158/2159-8290.CD-15-1483 ↗
54. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies10.1039/C8LC00100F ↗
55. Review: microfluidics technologies for blood-based cancer liquid biopsies10.1016/j.aca.2017.12.050 ↗
56. Microfluidic approaches for isolation, detection, and characterization of extracellular vesicles: current status and future directions10.1016/j.bios.2016.12.062 ↗
57. Circulating breast cancer cells are frequently apoptotic10.1016/S0002-9440(10)61667-7 ↗
58. Role of circulating tumor cells in future diagnosis and therapy of cancer10.4103/2394-4722.158803 ↗
59. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters10.1073/pnas.1508541113 ↗
60. Frequent EpCam protein expression in human carcinomas10.1016/j.humpath.2003.08.026 ↗
61. Benchtop technologies for circulating tumor cells separation based on biophysical properties
62. Circulating tumor cell detection: a direct comparison between negative and unbiased enrichment in lung cancer10.3892/ol.2017.6046 ↗
63. Isolation of rare circulating tumour cells in cancer patients by microchip technology10.1038/nature06385 ↗
64. Detection of mutations in EGFR in circulating lung-cancer cells10.1056/NEJMoa0800668 ↗
65. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody10.1039/B917959C ↗
66. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip10.1039/C3LC51017D ↗
67. Arrayed microfluidic chip for detection of circulating tumor cells and evaluation of drug potency10.1016/j.ab.2018.10.011 ↗
68. Microfluidic continuum sorting of sub-populations of tumor cells via surface antibody expression levels10.1039/C6LC01496H ↗
69. Epithelial and mesenchymal circulating tumor cell isolation and discrimination using dual-immunopatterned device with newly-developed anti-63B6 and anti-EpCAM10.1016/j.snb.2017.12.157 ↗
70. Epithelial cancer biomarker EpCAM determination in peripheral blood samples using a microfluidic immunosensor based in silver nanoparticles as platform10.1016/j.snb.2015.06.066 ↗
71. Tunable thermal-sensitive polymer–graphene oxide composite for efficient capture and release of viable circulating tumor cells10.1002/adma.201600658 ↗
72. NanoVelcro chip for CTC enumeration in prostate cancer patients10.1016/j.ymeth.2013.06.019 ↗
73. A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells10.1016/j.ymeth.2013.05.027 ↗
74. An integrated microfluidic chip for one-step isolation of circulating tumor cells10.1016/j.snb.2016.05.163 ↗
75. Versatile exclusion-based sample preparation platform for integrated rare cell isolation and analyte extraction10.1039/C8LC00620B ↗
76. Cancer cell separator using size-dependent filtration in microfluidic chip10.1016/j.snb.2013.04.030 ↗
77. Highly sensitive enumeration of circulating tumor cells in lung cancer patients using a size-based filtration microfluidic chip10.1016/j.bios.2013.07.044 ↗
78. Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer
79. A microfluidic chip integrated with a high-density PDMS-based microfiltration membrane for rapid isolation and detection of circulating tumor cells10.1016/j.bios.2015.04.080 ↗
80. High-throughput microfluidic labyrinth for the label-free isolation of circulating tumor cells10.1016/j.cels.2017.08.012 ↗
81. Tunable particle separation in a hybrid dielectrophoresis (DEP)- inertial microfluidic device10.1016/j.snb.2018.04.020 ↗
82. The utilization of optically-induced-dielectrophoresis (ODEP)-based virtual cell filters in a microfluidic system for continuous isolation and purification of circulating tumour cells (CTCs) based on their size characteristics10.1016/j.snb.2016.10.075 ↗
83. Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device10.1039/C6LC01279E ↗
84. Spiral shape microfluidic channel for selective isolating of heterogenic circulating tumor cells10.1016/j.bios.2017.10.036 ↗
85. High-purity capture of CTCs based on micro-beads enhanced isolation by size of epithelial tumor cells (ISET) method10.1016/j.bios.2017.11.026 ↗
86. Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: mechanisms and clinical applications10.18632/oncotarget.18277 ↗
87. Microfluidic flow fractionation device for label-free isolation of circulating tumor cells (CTCs) from breast cancer patients10.1016/j.bios.2012.07.021 ↗
88. Optically-induced-dielectrophoresis (ODEP)-based cell manipulation in a microfluidic system for high-purity isolation of integral circulating tumor cell (CTC) clusters based on their size characteristics10.1016/j.snb.2017.12.003 ↗
89. Two-stage microfluidic chip for selective isolation of circulating tumor cells (CTCs)10.1016/j.bios.2014.07.019 ↗
90. Microfluidic immunomagnetic cell separation from whole blood10.1016/j.jchromb.2015.12.016 ↗
91. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors10.1158/1078-0432.CCR-15-2548 ↗
92. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells10.1021/nn9011225 ↗
93. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles
94. Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers
95. Phase I study of liposome irinotecan (PEP02) in combination with weekly infusion of 5-FU/LV in advanced solid tumors
96. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer10.1200/JCO.2005.04.937 ↗
97. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia10.1111/j.1365-2141.2008.07400.x ↗
98. Cancer nanomedicine: a review of recent success in drug delivery10.1186/s40169-017-0175-0 ↗
99. A phase II trial of genexol-PM and gemcitabine in patients with advanced non-small-cell lung cancer10.1007/s00280-014-2498-5 ↗
100. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies10.1158/1078-0432.CCR-03-0655 ↗